Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Top 20 Animal Health Companies in the World

In this article, we will take a detailed look at the Top 20 Animal Health Companies in the World with insights into the revenue generated in 2022. For a quick overview of the top 5 animal health companies, read our article Top 5 Animal Health Companies in the World.

The animal health industry is in solid shape for continued growth despite global economic downturns in 2020 due to COVID-19. Medium to long-term livestock and companion animal market trends are essential in determining future market behaviors in the related animal health industry.

The global animal health market is expected to grow at a CAGR of 3.36% from 2023 to 2028, reaching US$45.2 billion by 2028. This growth is driven by several factors, including increasing number of pet owners and their desire for high-quality veterinary care, rising awareness of zoonotic diseases, and numerous technological advancements.

According to Bloomberg, the pet economy is expected to grow more than 50% in coming years, driven by spending on sophisticated drugs and treatments and pampering. The pandemic pet boom added 5 million new pets to U.S. households, a 4% increase. This surge in pet ownership is fueling the growth of the animal healthcare industry. Pet owners are increasingly willing to invest in their pets’ health and well-being, leading to demand for more sophisticated drugs and treatments.

A Look into the Animal Healthcare Industry

Zoetis Inc. (NYSE: ZTS), the world’s largest producer of medicine and vaccinations for pets and livestock, reported a solid second quarter of 2023. The company saw a 9% operational revenue growth and 12% operational adjusted net income growth. This was driven by a diverse portfolio across markets and species. Segment growth was more balanced this quarter, with 11% active growth internationally and 7% growth in the U.S. operations. The first half has primarily been as expected, with 6% operational revenue growth. However, Zoetis Inc. (NYSE: ZTS) expects more substantial growth in the year’s second half, especially in its U.S. companion animal business.

Additionally, in livestock, which has grown 8% year-to-date on an operational basis, Zoetis anticipates unfavorable comparisons in the second half due to the timing of price decreases in Jackson in the U.S. last year and resumption of supply of several products after outages in the first half of 2022.

Elanco Animal Health, Inc. (NYSE:ELAN), a $4.5 billion market cap company, posted a loss of $78 million in its most recent financial year. However, analysts expect Elanco Animal Health, Inc. (NYSE:ELAN) to reach the break-even point in 2024 after incurring a final loss in 2023. This is good news for investors, as it suggests that Elanco Animal Health, Inc. (NYSE:ELAN) is on the right track.

Importance of R&D Investments in the Animal Healthcare Industry

Two leaders in the animal health sector, Kathy Turner of IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Rob Kelly of Zoetis Inc. (NYSE:ZTS), believe that companies should continue to invest in R&D during the current economic downturn. They acknowledge that it will be difficult for all firms to maintain the same level of pre-COVID-19 spending, but they argue that R&D is essential to the industry’s long-term success. European animal healthcare companies spend 8% of revenue on R&D, investing over €600 million annually in new product development.

didesign021/Shutterstock.com

Methodology

To rank the top 20 animal health companies in the world, we sourced data from Pharma Shots and Fierce Pharma. We have mentioned annual revenue with each company.

Top 20 Animal Health Companies in the World

  1. Immucell Corp (NASDAQ:ICCC)

Annual Revenue in 2022 (Million USD): 19

ImmuCell Corp (NASDAQ:ICCC), an animal health company, develops, manufactures, and markets products that improve the health and productivity of dairy and beef cattle in the United States and internationally. However, the company’s earnings have declined by an average of 10.5% per year over the past five years.

  1. Dechra

Annual Revenue in 2022 (Million USD):  827

Swedish investment firm E.Q.T. proposes acquiring Dechra Pharmaceuticals in an all-cash deal worth £4.6 billion ($5 billion). This represents a premium of 51% on Dechra’s closing stock price, making it one of the most significant potential UK take-private deals this year.

  1. Animal Care Group Plc

Annual Revenue in 2022 (Million USD): 86.9 

Animal Care Group Plc, a UK-based international veterinary pharmaceutical company, develops and markets prescription and over-the-counter products that improve animal health and well-being. The company operates in three categories: companion animals, equine and other, and production animals. Its essential product is Daxocox, a differentiated COX-2 inhibitor for treating chronic pain in dogs.

  1. SeQuent

Annual Revenue in 2022 (Million USD): 170

SeQuent has rapidly become India’s leading animal health company, establishing a global niche with its unique business model. The company has grown from acquiring and integrating businesses in key international markets to successfully scaling and consolidating its operations.

  1. KRKA

Annual Revenue in 2022 (Million USD): 1.7

KRKA d.d. shareholders have enjoyed a total shareholder return (TSR) of 30% over the past year, including dividends. This exceeds the company’s five-year average T.S.R. of 21%, suggesting that investor sentiment is positive.

  1. Vibrac

Annual Revenue in 2022 (Million USD): 195.3

Virbac will continue accelerating in 2023 on two key dimensions: R&D and capital expenditures. Virbac plans to boost its R&D investment to around 8.5% of revenues in 2023 and increase its capital expenditure investments to approximately €100 million. This will help the company prepare for the future, accompany its growth, and increase its medium-term productivity.

  1. Heska Corp (NASDAQ:HSKA)

Annual Revenue in 2022 (Million USD): 257 

According to the Q4 2022 Heska Corp (NASDAQ:HSKA) earnings call, the company had a strong Q4 in 2022, with solid execution, significant investment, and preparation for good momentum entering 2023. The company continued to gain market share, significantly improve gross margin, and deliver 15% to 18% growth in crucial subscription metrics. 2022 was an excellent year for Heska (NASDAQ:HSKA), with a solid performance in premium chemistry analyzer placements, up 28% in the fourth quarter year-over-year.

  1. Norbrook

Annual Revenue in 2022 (Million USD): 281

Norbrook, a leading global provider of veterinary pharmaceuticals, enhances the health of farm and companion animals through growth and innovation. The company aims to provide a balanced portfolio of products to its customers and end users, focusing on developing new veterinary products, being the first generic to market where possible, and differentiating its products through features and benefits.

  1. OuroFino

Annual Revenue in 2022 (Million USD): 340.87

Ourofino, a Brazilian veterinary pharmaceutical company, develops, produces, and sells veterinary drugs, vaccines, and other veterinary products for production and companion animals. In 2022, Ourofino’s net revenue exceeded R$ 1 billion, a 15% increase over 2021. EBITDA reached R$ 207.2 million, a 20.1% increase over 2021.

  1. Neogen Corp (NASDAQ:NEOG)

Annual Revenue in 2022 (Million USD): 527

Neogen Corp (NASDAQ:NEOG) experienced higher-than-normal input cost inflation in fiscal 2023, impacting operating results. While pricing actions mitigated some inflationary pressures, ongoing inflation could impact customer purchasing decisions and order patterns in fiscal 2024, albeit at a decreasing rate.

  1. Vetoquinol

Annual Revenue in 2022 (Million USD): 570

In 2022, Vetoquinol reported sales of €540m and net income of €63m from farm and pet animal healthcare products. Vetoquinol adopted its new strategic plan in 2022, setting its direction and roadmap for the next five years.

  1. Eco Animal Health

Annual Revenue in 2022 (Million USD): 82.19

Eco Animal Health Group plc is a UK-based animal health company that develops, registers, and markets pharmaceutical products for global markets. Its patented drug, Aivlosin, is a macrolide antibiotic for treating respiratory and enteric diseases in pigs and poultry. The company also offers generic endectocides and other antiparasitic drugs, such as Ecomectin, Ecoheart, Ecotraz, and Ecomintic.

  1. Phibro Animal Health Corp (NASDAQ:PAHC)

Annual Revenue in 2022 (Million USD): 942

Phibro Animal Health Corp’s (NASDAQ:PAHC) net sales increased 5% to $244.6 million in Q4 2022, while net income decreased 59% to $7.2 million. Despite the decline in net income, Phibro’s sales growth of more than 20% in 2022 put it in the top tier of animal health companies.

  1. Orion

Annual Revenue in 2022 (Million USD): 1,412 

In 2023, net sales of Orion are expected to be slightly higher than in 2022, excluding EUR 228m ODM-208 upfront payment (2022 net sales without ODM-208 upfront payment: EUR 1,113m).

  1. IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Annual Revenue in 2022 (Million USD): 3,367

IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported strong financial results for Q2 of 2023, with revenue up 10% reported and 10% organic to $1.07 billion.

Click to continue reading and see the Top 5 Animal Health Companies in the World.

Suggested Articles:

Disclosure. None. Top 20 Animal Health Companies in the World is originally published on Insider Monkey.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

  • It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
  • It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
  • It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

  • The AI infrastructure supercycle
  • The onshoring boom driven by Trump-era tariffs
  • A surge in U.S. LNG exports
  • And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months

• BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.

• One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Content: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…